Incyte study shows good response to treatment for some PV blood cancer patients

205
Advertisement

Jakafi-300x131Incyte Corporation, Wilmington,   announced  promising  28-week data from the Phase 3 RESPONSE-2 study of its flagship blood cancer drug Jakafi.

The data show that Jakafi was superior to best available therapy for some patients with polycythemia vera (PV) who resist other treatments.

PV is a less common form of slow-growing blood cancer that leads to the production of too many red blood cells.

The findings were presented at the 21st Congress of the European Hematology Association (EHA) in Copenhagen, Denmark.

“We are pleased with the RESPONSE-2 study results presented at EHA, which reinforce the superiority of Jakafi over best available therapy in achieving hematocrit control, without phlebotomy, in patients with inadequately controlled PV without enlarged spleens,” said Steven Stein, M.D., Incyte’s chief medical officer. “These results are meaningful to patients with uncontrolled PV who have few other treatment options to help manage their disease.”

Advertisement

Additionally, the RESPONSE-2 study demonstrated that nearly five times more patients with PV achieved complete hematologic remission with Jakafi compared to BAT at 28 weeks (23.0 percent vs 5.3 percent.

Advertisement
Advertisement